Invesco Ltd. has disclosed a significant ownership stake in Ligand Pharmaceuticals Inc. in its recent filing. The firm reported holding 1,520,911 shares, which accounts for 7.6% of Ligand's total stock. This information is crucial as it reflects Invesco's influence in the investment advice sector.

Invesco Ltd., a prominent player in the financial services industry, is classified under the Standard Industrial Classification (SIC) code 6282, which pertains to Investment Advice. The company is publicly traded on the New York Stock Exchange under the ticker symbol IVZ. Invesco has been active in filing various reports, including recent forms such as the 13F-HR and multiple Schedule 13G/A submissions.

The filing states that Invesco beneficially owns 1,520,911 shares of Ligand Pharmaceuticals, with 1,497,232 shares having sole voting power. Invesco's clients hold the shares, and the company acts as a parent holding entity for its investment advisers. The filing indicates that no single client has more than 5% economic ownership of the shares, which are held for investment purposes.

This disclosure may impact various stakeholders, including investors and analysts monitoring Ligand Pharmaceuticals and the broader investment advice sector. Invesco's substantial stake could influence market perceptions and strategies related to Ligand's performance.

Looking ahead, Invesco may file additional updates or disclosures as it continues to manage its investment portfolio. The filing does not specify what actions may follow this disclosure.